Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 43 of 112 for:    Chronic Fatigue Syndrome

Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CONNeCT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03186027
Recruitment Status : Unknown
Verified June 2017 by Hospital Universitari Vall d'Hebron Research Institute.
Recruitment status was:  Recruiting
First Posted : June 14, 2017
Last Update Posted : June 29, 2017
Sponsor:
Collaborator:
VITAE NATURAL NUTRITION, S.L.
Information provided by (Responsible Party):
Hospital Universitari Vall d'Hebron Research Institute

Brief Summary:
The main aim of the study is to examine the effect of oral CoQ10 plus NADH (Reconnect®) supplementation twice daily for 8-weeks on the changes in fatigue perception, sleep disturbances, autonomic dysfunction and HRQoL assessed by patient-reported outcome measures in CFS/ME.

Condition or disease Intervention/treatment Phase
Chronic Fatigue Syndrome Dietary Supplement: Coenzyme Q10 plus NADH Dietary Supplement: phosphoserine plus vitamin C Not Applicable

Detailed Description:

Chronic Fatigue Syndrome, as known as Myalgic Encephalomyelitis (CFS/ME) is a complex and extremely debilitating chronic condition, with no known cause, no established diagnostic tests, and no universal effective therapy. Its symptoms are mainly unexplained disabling fatigue that lasts for six months or more and that does not improve with rest, worsing with physical and mental activity. It is associated with other concomitant symptoms including muscle pain, post-exertional malaise lasting more than 24h, unrefreshing sleep, autonomic dysfunction and cognitive problems worsing quality of life of sufferers. Previous studies have shown that CFS/ME subjects have a significant decrease in CoQ10 and NADH levels in plasma and peripheral blood mononuclear cells (PBMCs), correlating with symptoms of the condition. Hypothesis: CoQ10 plus NADH administration could be beneficial in the improvement of outcome measures and molecular parameters in CFS/ME individuals.

A total of 282 potentially eligible Caucasian CFS/ME subjects who meet both the 1994 Centers for Disease Control and Prevention/Fukuda's definition and 2003 Canadian case criteria for CFS/ME will be initially enrolled in the study. Those patients who don't meet the inclusion criteria will excluded of the study. All participants will be treatment with ReConnect® containing CoQ10 (50 mg) plus NADH (5 mg) vs. placebo twice daily for 8-weeks in term. Scores for fatigue perception, sleep problems, autonomic dysfunction and QoL will be assess by validated questionnaires of Fatigue Impact Scale (FIS-40), Pittsburgh Sleep Quality Index (PSQI), COMPASS-31 and HRV recording device, and HRQoL (36 item Short Form Health survey), respectively.

The primary outcome is to evaluate the efficacy of oral CoQ10 plus NADH (Reconnect®) supplementation twice daily for 8-weeks on the changes in fatigue perception, sleep problems, autonomic dysfunction and health-related quality of life assessed by outcome measures in CFS/ME subjects.

The secondary outcomes are to examine the effect of oral Reconnect® administration on fatigue perception (assessed by FIS-40), sleep disruption (PSQI), autonomic function (COMPASS-31), Heart Rate Variability (HRV) for measuring R-R intervals by mobile device coupled to the Polar H7 thoracic belt and HRQoL (36-items Short Form Health survey).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 282 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Active Dietary Supplement: ReConnect (CoQ10 plus NADH) and excipients. ReConnect supplementation (CoQ10: 200mg/day plus NADH 20 mg/day) divided into 2 daily dose (2 tablets/ before breakfast and 2 tablets/ before lunch).

Excipient Dietary Supplement: Placebo (serine plus vitamin C) Placebo supplementation divided into two daily dose (2 tablets/before breakfast and 2 tablets/ before lunch)

Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: The investigator, care provider and participants do not know which individuals have been assigned in each arm or comparison group.
Primary Purpose: Treatment
Official Title: Effect of Coenzyme Q10 Plus NADH Supplementation on the Changes in Fatigue Perception, Sleep Disturbances, Autonomic Function and Health-related Quality of Life in CFS/ME - A Randomized, Placebo-controlled, Double-blind Trial.
Actual Study Start Date : June 28, 2017
Estimated Primary Completion Date : October 31, 2018
Estimated Study Completion Date : December 31, 2018


Arm Intervention/treatment
Active Comparator: Active supplement (CoQ10 plus NADH)

CFS/ME patients will be randomized to evaluate the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH: 20 mg/day) taking 4 tablets/day during 8-weeks in term.

Active supplement based on Coenzyme Q10 plus NADH

Dietary Supplement: Coenzyme Q10 plus NADH

Active arm: Coenzyme Q10 plus NADH CFS/ME patients who will be randomized to measure the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH 20 mg/day; 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.

Intervention: Reconnect


Placebo Comparator: Phosphoserine plus vitamin C

CFS/ME patients will be randomized to assess the effect of placebo (phospho-serine plus vitamin C) taking 4 tablets/day for 8-weeks in term.

Placebo: phosphoserine plus vitamin C

Dietary Supplement: phosphoserine plus vitamin C

Placebo arm: phosphoserine plus vitamin C CFS/ME patients who will be randomized to measure the effect of oral Placebo supplementation (phosphoserine and vit C, 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.

Intervention: placebo





Primary Outcome Measures :
  1. Effect of oral Reconnect ® (CoQ10 plus NADH) supplementation on the changes in core symptoms during 8-weeks in CFS/ME subjects. [ Time Frame: At the beginning (session 2, week 1), intermedium stage (session 3, week 4) and at the close-up of study (session 4, week 8) ]
    Evaluate the effect of oral Reconnect ® supplementation on the changes in fatigue perception measured by the Fatigue Index Scale-40 (40 items) in all study participants. Items Rate: 0 (no fatigue) to 4 (severe fatigue).


Secondary Outcome Measures :
  1. Demographic data and clinical parameters [ Time Frame: At the beginning (session 2, week 1), intermedium stage (session 3, week 4) and at the close-up of study (session 4, week 8) ]
    Sex

  2. Age of onset of symptoms [ Time Frame: At the beginning (session 2, week 1), intermedium stage (session 3, week 4) and at the close-up of study (session 4, week 8) ]
    Age at onset of fatigue

  3. Concomitant conditions [ Time Frame: At the beginning (session 2, week 1), intermedium stage (session 3, week 4) and at the close-up of study (session 4, week 8) ]
    Comorbid illnesses associated with ME/CFS

  4. Height will be measured and reported [ Time Frame: At the beginning (session 2, week 1), intermedium stage (session 3, week 4) and at the close-up of study (session 4, week 8) ]
    Height in meters

  5. Weight will be measured and reported [ Time Frame: At the beginning (session 2, week 1), intermedium stage (session 3, week 4) and at the close-up of study (session 4, week 8) ]
    Weight in kilograms

  6. Body Mass Index (BMI) [ Time Frame: At the beginning (session 2, week 1), intermedium stage (session 3, week 4) and at the close-up of study (session 4, week 8) ]
    Height and Weight will be combined to report BMI in kg/m^2

  7. Sleep Quality [ Time Frame: At the beginning (session 2, week 1), intermedium stage (session 3, week 4) and at the close-up of study (session 4, week 8) ]
    Pittsburgh Quality of Sleep Index (18 items) for non-refreshing sleep

  8. Autonomic Function [ Time Frame: At the beginning (session 2, week 1), intermedium stage (session 3, week 4) and at the close-up of study (session 4, week 8) ]
    COMPASS-31 Questionnaire (31-items) to assess autonomic dysfunction

  9. Heart Rate Variability (HRV) recording device [ Time Frame: At the beginning (session 2, week 1), intermedium stage (session 3, week 4) and at the close-up of study (session 4, week 8) ]
    Time domain - NN (normal-to-normal R-R interval), HRV index (total number of all NN/ the height of the histogram of all NN), SDNN (standard deviation of the NN), RMSSD (the root mean square of differences of successive NN), NN50 (number of pairs of adjacent NN intervals differing by more than 50 ms in the entire recording) and pNN50(NN50/total number of all NN). Frequency domain - TP (the variance of NN intervals over the temporal segment), VLF(power in very low frequency range; < 0.04 Hz), LF (Power in low frequency range; 0.04~0.15 Hz), HF(Power in high frequency range; 0.15~0.4 Hz).

  10. Health-Related Quality of Life SF36 survey [ Time Frame: At the beginning (session 2, week 1), intermedium stage (session 3, week 4) and at the close-up of study (session 4, week 8) ]
    Short Form-36 Health Survey (36-items) to measure quality of life of participants.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients female between 18 and 65 years old.
  2. Body Mass Index (BMI) ≤ 30 mg/m²
  3. Subjects who met the 1994 Centers for Disease Control and Prevention/Fukuda definition and 2003 Canadian diagnostic criteria for CFS/ME.
  4. Patients must be able to participate, understand and complete questionnaires in Spanish language.
  5. Patients who give a signed informed consent before initiating the study.

Exclusion Criteria:

  1. Patients who do not fulfilled the 1994 Centers for Disease Control and Prevention/Fukuda definition and 2003 Canadian criteria for CFS/ME.
  2. Patients who are participating in another clinical trial of the same or different nature in the last 30 days prior to inclusion.
  3. Any participants who, in the opinion of the principal investigator, may not be able to follow instructions or make a good treatment compliance.
  4. Subjects that don't give signed informed consent to participate in the study.
  5. Participants who are receiving any drug or banned substances and is expected that withdrawal of some medications/products not allowed in the study involves a significant problem.
  6. Participants who are pregnant and/or breastfeeding,
  7. Participants with autoimmune disorder, cancer, endocrine and metabolic disorders, rheumatic conditions, multiple sclerosis, psychosis, major depression, cardiovascular disease, hematological conditions, use of oral anticoagulants, smokers or had a history of substance abuse.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03186027


Contacts
Layout table for location contacts
Contact: Jesus Castro, PhD +34 93 4893000 ext 4927 jesus.castro@vhir.org
Contact: Maria J. Segundo, PhD +34 667662374 msegundo@vitae.es

Locations
Layout table for location information
Spain
Vall d'Hebron University Hospital Recruiting
Barcelona, Spain, 08035
Contact: Jose Alegre, MD; PhD    +34 934893000 ext 4927    jalegre@vhebron.net   
Contact: Jesus Castro, PhD    +34 934893000 ext 4927    jesus.castro@vhir.org   
Sponsors and Collaborators
Hospital Universitari Vall d'Hebron Research Institute
VITAE NATURAL NUTRITION, S.L.
Investigators
Layout table for investigator information
Principal Investigator: Jose Alegre, MD; PhD Vall d'Hebron University Hospital (CFS/ME Clinical Unit)

Additional Information:
Publications of Results:

Layout table for additonal information
Responsible Party: Hospital Universitari Vall d'Hebron Research Institute
ClinicalTrials.gov Identifier: NCT03186027     History of Changes
Other Study ID Numbers: VITAE 2015
First Posted: June 14, 2017    Key Record Dates
Last Update Posted: June 29, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hospital Universitari Vall d'Hebron Research Institute:
chronic fatigue
Sleep problems
Autonomic dysfunction
Health-Related Quality of Life
Coenzyme Q10
NADH
Additional relevant MeSH terms:
Layout table for MeSH terms
Fatigue Syndrome, Chronic
Syndrome
Fatigue
Disease
Pathologic Processes
Signs and Symptoms
Virus Diseases
Muscular Diseases
Musculoskeletal Diseases
Encephalomyelitis
Central Nervous System Diseases
Nervous System Diseases
Neuromuscular Diseases
Vitamins
Ascorbic Acid
Coenzyme Q10
Ubiquinone
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents